This trial is an open-label, multi-center, randomized, controlled feasibility trial.~All participants will undergo surgical debridement and receive either Stimulan-VG and an abbreviated course of systemic antibiotic therapy (3 days ±2 days) or a full course (4-6 weeks) of systemic antibiotic therapy.~The total duration of study is Approximately 55 weeks.
The purpose of this trial is to evaluate the safety and between-group effect size of Stimulan-VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO) of the forefoot.